Cargando…

Tumor mutational burden is not predictive of cytotoxic chemotherapy response

BACKGROUND: High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikanjam, Mina, Riviere, Paul, Goodman, Aaron, Barkauskas, Donald A., Frampton, Garrett, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458654/ https://www.ncbi.nlm.nih.gov/pubmed/32923144 http://dx.doi.org/10.1080/2162402X.2020.1781997

Ejemplares similares

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[(18)F]FDG PET (positron emission tomography) scan in cancer patients
por: Haghighat Jahromi, Amin, et al.
Publicado: (2020)

MHC-I genotype and tumor mutational burden predict response to immunotherapy
por: Goodman, Aaron M., et al.
Publicado: (2020)

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
por: Pham, Timothy V., et al.
Publicado: (2021)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
por: Pham, Timothy V., et al.
Publicado: (2020)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
por: Jardim, Denis L., et al.
Publicado: (2020)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience
por: Nikanjam, Mina, et al.
Publicado: (2018)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
por: Goodman, Aaron M., et al.
Publicado: (2017)

Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019)

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers
por: Vu, Peter, et al.
Publicado: (2020)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse
por: Castro, Andrea, et al.
Publicado: (2023)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
por: Boichard, Amélie, et al.
Publicado: (2018)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
por: Charo, Lindsey M., et al.
Publicado: (2020)

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
por: Ikeda, Sadakatsu, et al.
Publicado: (2016)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups
por: Asmann, Yan W., et al.
Publicado: (2021)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
por: Bohan, Sandy S., et al.
Publicado: (2020)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications
por: Cohen, Philip R., et al.
Publicado: (2015)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
por: Franses, Joseph W, et al.
Publicado: (2022)

High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
por: Boichard, Amélie, et al.
Publicado: (2017)

Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer
por: Hougen, Helen Y., et al.
Publicado: (2023)

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics
por: Jardim, Denis L., et al.
Publicado: (2021)

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
por: Li, Alex M., et al.
Publicado: (2019)

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
por: Kato, Shumei, et al.
Publicado: (2020)

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors
por: Shao, Changxia, et al.
Publicado: (2020)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
por: Adashek, Jacob J., et al.
Publicado: (2021)

Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
por: Sharabi, Andrew, et al.
Publicado: (2017)

Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas
por: de Pádua Covas Lage, Luís Alberto, et al.
Publicado: (2022)

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
por: Friedman, Claire F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_89b7kkoiml9q6u3digpu8btkua